Reference Interval:
Susceptible, intermediate, susceptibility is dose dependent (SSD), not susceptible, or resistant. Interpretive guidelines are provided only for Candida species.
|
| Interpretive Data: |
SDD = susceptibility is dose dependent.
NONS=Not Susceptible
NONE=Interpretive guidelines are not available
For amphotericin B, there are no CLSI breakpoints, but MIC greater than 1 is considered resistant.
Flucytosine MIC breakpoints are based largely on historical data and partially on the drug's pharmacokinetics.
For fluconazole the guidelines are based on experience with mucosal and invasive infections due to Candida species. When the isolate is C. glabrata and the MIC is less than or equal to 32 µg/mL the maximum dosage regimen should be used.
For intraconazole, the data are based entirely on experience with mucosal infections, and data supporting breakpoints for invasive infections due to Candida spp. are not available.
Voriconazole MIC interpretation is used as surrogate for posaconazole interpretation.
Susceptible Dose Dependent (SDD) applies to fluconazole and itraconazole. Susceptible is dependent on achieving the maximum possible level.
For anidulafungin, caspofungin and micafungin, the data are based substantially on experience with non-neutropenic patients with candidemia. Clinical relevance in other settings is uncertain.
Susceptibility testing is performed by CLSI-approved broth microdilution method.
Please refer to Statement B in the Compliance Statements section in the front of the Laboratory Test Directory.
|
| Note: |
Yeast identification is required for fluconazole interpretation. Isolates submitted without the species identification noted will be tested and identified at ARUP for an additional charge.
The following agents will be tested: amphotericin B, anidulafungin, caspofungin, fluconazole, 5-fluorocytosine, itraconazole, micafungin, posaconazole and voriconazole.
|
| CPT Code(s): |
87186
|
Cross References: |
Yeast Susceptibility Panel |
|